Danaher Corp DHR
We take great care to ensure that the data presented and summarized in this overview for DANAHER CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DHR
View all-
Vanguard Group Inc Valley Forge, PA60.1MShares$16 Billion0.3% of portfolio
-
Black Rock Inc. New York, NY49.7MShares$13.2 Billion0.29% of portfolio
-
State Street Corp Boston, MA27.8MShares$7.38 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA26.7MShares$7.1 Billion1.21% of portfolio
-
Morgan Stanley New York, NY16.5MShares$4.38 Billion0.33% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD16.2MShares$4.29 Billion0.49% of portfolio
-
Capital International Investors Los Angeles, CA15.1MShares$4.01 Billion0.78% of portfolio
-
Geode Capital Management, LLC Boston, MA12.9MShares$3.43 Billion0.3% of portfolio
-
Jpmorgan Chase & CO New York, NY11MShares$2.92 Billion0.25% of portfolio
-
Franklin Resources Inc San Mateo, CA8.04MShares$2.14 Billion0.66% of portfolio
Latest Institutional Activity in DHR
Top Purchases
Top Sells
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Insider Transactions at DHR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 16
2024
|
Rainer Blair President & CEO |
SELL
Open market or private sale
|
Direct |
9,005
-7.76%
|
$2,386,325
$265.0 P/Share
|
May 15
2024
|
Alan G Spoon Director |
BUY
Grant, award, or other acquisition
|
Direct |
390
+0.33%
|
-
|
May 15
2024
|
Raymond C Stevens Director |
BUY
Grant, award, or other acquisition
|
Direct |
390
+3.36%
|
-
|
May 15
2024
|
William King SVP, Strategic Development |
SELL
Payment of exercise price or tax liability
|
Direct |
7,018
-12.71%
|
$1,845,734
$263.46 P/Share
|
May 15
2024
|
William King SVP, Strategic Development |
BUY
Exercise of conversion of derivative security
|
Direct |
12,623
+18.61%
|
$631,150
$50.37 P/Share
|
May 15
2024
|
Christopher Paul Riley Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
320
-2.15%
|
$84,160
$263.46 P/Share
|
May 15
2024
|
Jessica L Mega Director |
BUY
Grant, award, or other acquisition
|
Direct |
390
+12.52%
|
-
|
May 15
2024
|
John T Schwieters Director |
BUY
Grant, award, or other acquisition
|
Direct |
390
+2.31%
|
-
|
May 15
2024
|
Feroz Dewan Director |
BUY
Grant, award, or other acquisition
|
Direct |
390
+14.93%
|
-
|
May 15
2024
|
A Shane Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
390
+10.66%
|
-
|
May 15
2024
|
Georgeann Couchara SVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
281
-5.16%
|
$73,903
$263.46 P/Share
|
May 15
2024
|
Teri List Director |
BUY
Grant, award, or other acquisition
|
Direct |
390
+1.9%
|
-
|
May 15
2024
|
Joakim Weidemanis Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,079
-3.41%
|
$809,777
$263.46 P/Share
|
May 15
2024
|
Linda Filler Director |
BUY
Grant, award, or other acquisition
|
Direct |
390
+0.94%
|
-
|
May 15
2024
|
Elias A. Zerhouni Director |
BUY
Grant, award, or other acquisition
|
Direct |
390
+1.13%
|
-
|
May 15
2024
|
Pardis C Sabeti Director |
BUY
Grant, award, or other acquisition
|
Direct |
390
+6.88%
|
-
|
May 14
2024
|
Rainer Blair President & CEO |
SELL
Open market or private sale
|
Direct |
19,085
-14.13%
|
$4,866,675
$255.0 P/Share
|
May 14
2024
|
Rainer Blair President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,085
+6.76%
|
$1,145,100
$60.72 P/Share
|
May 10
2024
|
Matthew Mc Grew EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
46,377
-33.65%
|
$11,733,381
$253.07 P/Share
|
May 10
2024
|
Matthew Mc Grew EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,174
+22.65%
|
$1,510,440
$60.66 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 60.2K shares |
---|---|
Exercise of conversion of derivative security | 221K shares |
Open market or private sale | 250K shares |
---|---|
Payment of exercise price or tax liability | 79.7K shares |
Bona fide gift | 976 shares |